Amgen Changes Direction In Government Affairs; Beier Succeeds Teeley
Executive Summary
Amgen's new senior VP-global government affairs is former Genentech exec David Beier
You may also be interested in...
Procrit, Aranesp Reimbursement Adjusted; CMS Splits The Difference
The new payment formula for J&J's Procrit (epoetin alfa) and Amgen's Aranesp (darbepoetin alfa) under the Medicare Hospital Outpatient Prospective Payment System reflects the ratio of dosing used by Medicare providers in chemotherapy patients, CMS said
Hogan & Hartson
David Beier joins D.C. law firm Hogan & Hartson as partner. Beier was former Vice President Gore's chief domestic policy adviser, and was Genentech's VP-government affairs from 1989-1998
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011